Nahdi Medical Company
4164.SR · SAU
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 8.62B | 3.52B | 1.00B | 887.81M | 6.83 |
| 2023 FY | 8.71B | 3.44B | 960.96M | 892.62M | 6.87 |
| 2024 FY | 9.45B | 3.53B | 873.19M | 820.72M | 6.31 |
| 2025 FY | 10.21B | 3.81B | 907.64M | 830.70M | 6.39 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 4.94B | 2.70B | 1.08B | 1.17B | 2.24B |
| 2023 FY | 5.37B | 2.91B | 909.66M | 1.17B | 2.46B |
| 2024 FY | 6.17B | 3.59B | 956.81M | 1.53B | 2.59B |
| 2025 FY | 6.69B | 3.95B | 554.44M | 1.78B | 2.74B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 1.67B | -275.23M | 1.39B | -300.30M | 675.27M |
| 2023 FY | 1.37B | -384.51M | 984.22M | -715.00M | -166.65M |
| 2024 FY | 1.49B | -384.50M | 1.11B | -715.00M | 47.15M |
| 2025 FY | 1.19B | -387.09M | 806.77M | -728.00M | -402.37M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 22.31B | 22.40B | — | — | — |
| 2023 FY | 17.81B | 18.08B | — | — | — |
| 2024 FY | 15.29B | 15.86B | — | — | — |
| 2025 FY | 12.35B | 13.58B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 2.53B | 965.95M | 260.64M | 238.40M | 1.83 |
| 2025 Q3 | 2.46B | 812.00M | 183.96M | 161.25M | 1.24 |
| 2025 Q4 | 2.59B | 1.08B | 211.19M | 175.88M | 1.35 |
| 2026 Q1 | 2.79B | 987.70M | 259.70M | 235.70M | 1.81 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 6.38B | 3.69B | 406.87M | 1.68B | 2.69B |
| 2025 Q3 | 6.76B | 4.25B | 636.68M | 1.80B | 2.52B |
| 2025 Q4 | 6.69B | 3.95B | 554.44M | 1.78B | 2.74B |
| 2026 Q1 | 7.41B | 4.80B | 1.12B | 1.77B | 2.62B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -124.15M | -89.66M | -213.81M | -1.41M | -580.96M |
| 2025 Q3 | 526.31M | -118.14M | 408.17M | -338.00M | 229.81M |
| 2025 Q4 | 138.56M | -91.62M | 46.94M | — | -82.24M |
| 2026 Q1 | 857.75M | -83.80M | 773.95M | — | 561.66M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 16.60B | 17.87B | — | — | — |
| 2025 Q3 | 15.47B | 16.63B | — | — | — |
| 2025 Q4 | 12.35B | 13.58B | — | — | — |
| 2026 Q1 | 13.69B | 14.34B | — | — | — |